Yahoovia Finnhub
SOUTH SAN FRANCISCO, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc. (“Lycia”) (Nasdaq: LYCA), a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins…
Yahoovia Finnhub
Lycia Therapeutics (LYCA) has moved quickly after its October IPO and filed a US$331.45 million shelf registration tied to an employee stock ownership plan covering 11,048,374 common shares. That rapid shelf registration comes on the heels of Lycia Therapeutics’ October IPO at…
Yahoovia Finnhub
As investors wait for the Claude developer to file its official IPO paperwork, several biotechs are going public and doing just fine.
SeekingAlphavia Finnhub
One biotech IPO debuted this week, while four IPOs submitted initial filings, including two sizable biotech filings. Read more here.
Yahoovia Finnhub
Investing.com -- Lycia Therapeutics Inc (NASDAQ:LYCA) surged nearly 33% in its Nasdaq debut on Friday after the clinical-stage biotechnology firm expanded its initial public offering to raise $317.5 million. The strong initial performance reflects robust investor appetite for…
Benzingavia Finnhub